Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients.
• Intravitreal corticosteroids are used to manage DME, but long-term effects require further investigation.
• Fluocinolone acetonide (FAc) is a corticosteroid implant used for DME treatment.

Purpose of the Study:

• To investigate the long-term effects of intravitreal Fluocinolone acetonide (FAc) on retinal morphology and function in patients with diabetic macular edema (DME).
• To assess changes in central macular thickness (CMT), best-corrected visual acuity (BCVA), cone b-wave, and photopic negative response (PhNR) over 24 months.
• To explore correlations between structural and functional parameters and treatment outcomes.

Main Methods:

• Retrospective evaluation of 17 eyes from 12 DME patients treated with intravitreal FAc.
• Assessment of retinal morphology via central macular thickness (CMT) measurements.
• Evaluation of retinal function through best-corrected visual acuity (BCVA) and electroretinography (cone b-wave and PhNR).

Main Results:

• A statistically significant reduction in mean CMT was observed from baseline (406.52 µm) to 24 months (310 µm) (p = 0.008).
• No significant changes were found in BCVA, cone b-wave, or PhNR amplitude at 24 months.
• Baseline CMT and PhNR amplitude were correlated with changes in CMT at follow-up, suggesting potential predictors of treatment response.

Conclusions:

• Intravitreal FAc provides a significant long-term reduction in retinal thickness for DME patients.
• The anti-edema effect appears more pronounced in patients with poorer baseline retinal morphology and function.
• Structure-function relationships may aid in identifying DME patients likely to benefit from FAc treatment.